首页> 外文期刊>Human Pathology >Diagnostic value of fine needle aspiration BRAF(V600E) mutation analysis in papillary thyroid cancer: a systematic review and meta-analysis
【24h】

Diagnostic value of fine needle aspiration BRAF(V600E) mutation analysis in papillary thyroid cancer: a systematic review and meta-analysis

机译:细针穿刺BRAF(V600E)突变分析在甲状腺乳头状癌中的诊断价值:系统评价和荟萃分析

获取原文
获取原文并翻译 | 示例
           

摘要

Fine needle aspiration (FNA) with cytologic analysis is an initial step in diagnosing thyroid nodules that are suspicious for cancer. We systematically reviewed the test accuracy of B-type Raf kinase (BRAF(V600E)) gene mutation analysis plus conventional FNA in the diagnosis of papillary thyroid cancer. We identified studies reporting BRAF(V600E) mutation analysis after FNA for evaluation of thyroid nodules through searching MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials, scanning reference lists of relevant studies, and contacting experts. Two independent reviewers screened literature results, abstracted data, and appraised study quality. When appropriate, bivariate and univariate random-effects meta-analyses of sensitivity and specificity were considered for all outcomes. Forty-seven studies met our inclusion criteria after screening 1560 citations and 169 full-text articles. The included studies enrolled approximately 16170 patients with 9924 FNA samples evaluated for BRAF(V600E) mutation. Univariate pooled sensitivity was 69% (95% confidence interval, 61%-76%) for papillary thyroid cancer. For thyroid nodules that were diagnosed cytologically as suspicious for papillary thyroid cancer, univariate pooled sensitivity using FNA and BRAF(V600E) results was 52% (95% confidence interval, 39%-64%). Despite its high specificity, our meta-analysis shows that BRAF(V600E) mutation analysis has a low sensitivity in diagnosing papillary thyroid cancer in thyroid nodules. The feasibility of this test as a single molecular tool is not well established, which indicates the need for well-designed prospective clinical studies. (C) 2015 Elsevier Inc. All rights reserved.
机译:细针穿刺(FNA)和细胞学分析是诊断可疑癌症的甲状腺结节的第一步。我们系统地回顾了B型Raf激酶(BRAF(V600E))基因突变分析和常规FNA在诊断甲状腺乳头状癌中的测试准确性。我们通过搜索MEDLINE,EMBASE和对照试验的Cochrane中央登记册,扫描相关研究的参考清单并联系专家,确定了FNA后报告BRAF(V600E)突变分析的研究,以评估甲状腺结节。两名独立的评审员筛选了文献结果,摘要数据和评估的研究质量。在适当的情况下,所有结果均应考虑敏感性和特异性的双变量和单变量随机效应荟萃分析。在筛选1560篇引文和169篇全文后,有47项研究符合我们的纳入标准。纳入的研究招募了约16170名患者,评估了9924个FNA样本的BRAF(V600E)突变。甲状腺乳头状癌的单因素综合敏感性为69%(95%置信区间,61%-76%)。对于在细胞学上被诊断为甲状腺乳头状癌可疑的甲状腺结节,使用FNA和BRAF(V600E)得出的单变量合并敏感性为52%(95%置信区间,39%-64%)。尽管其特异性很高,但我们的荟萃分析显示,BRAF(V600E)突变分析在诊断甲状腺结节中的乳头状甲状腺癌时灵敏度较低。该测试作为单一分子工具的可行性尚未得到充分证实,这表明需要精心设计的前瞻性临床研究。 (C)2015 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号